Rhenium (186Re) obisbemeda is under clinical development by Plus Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rhenium (186Re) obisbemeda’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rhenium (186Re) obisbemeda overview

Rhenium (186Re) obisbemeda is under development for the treatment of recurrent glioblastoma multiforme, kaposi sarcoma, lung adenocarcinoma, squamous cell carcinoma, breast cancer, head and neck squamous cell carcinoma, head and neck cancer, triple-negative breast cancer (TNBC), leptomeningeal peritoneal carcinomatosis, liver cancer, lung cancer, melanoma, ovarian carcinomatosis and pediatric brain cancers including ependymoma and high-grade glioma. It is administered through intertumoral, intrathecal and intraperitoneal routes. The drug candidate comprises of N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine (BMEDA)-conjugated to a chelated rhenium nanoliposomes and is being developed based on rhenium nanoliposome (RNL) technology. The drug candidate was also under development for the treatment of pediatric diffuse intrinsic pontine glioma.

Plus Therapeutics overview

Plus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. The company’s pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.

For a complete picture of Rhenium (186Re) obisbemeda’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.